South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced that its AI-powered mammography solution, Lunit INSIGHT MMG, will be implemented as an independent second reader across the entire Stockholm Region in Sweden, building on years of successful clinical validation and real-world use at Capio Saint Göran Hospital.
The deployment, carried out in collaboration with Sectra, will span three institutions: Capio Saint Göran Hospital, Karolinska University Hospital, and Södersjukhuset (Sös). Once fully implemented, the deployment is expected to support between 200,000 and 250,000 examinations annually.
The Stockholm deployment follows Lunit's earlier regional deployment in Dalarna, marking the company's second region-level deployment in Sweden. It builds on several years of clinical and operational experience at Saint Göran, where the solution progressed from prospective clinical evaluation to routine breast cancer screening.
Since its adoption in 2023, Lunit's AI solution has supported approximately 200,000 examinations over the past three years and has continued to support the screening workflow through changes in mammography systems, demonstrating its ability to operate at scale in a real-world screening environment.
The Stockholm Region deployment marks another important milestone in Lunit's expansion across Europe, demonstrating how clinical evidence, real-world validation, and routine implementation can translate into large-scale adoption of AI in population-based breast cancer screening.
